Why the study?
Does VP-16 compared to Vincristine plus Adriamycin improve response rates or survival in previously treated patients with metastatic breast cancer?
Does VP-16 compared to Vincristine plus Adriamycin improve response rates or survival in previously treated patients with metastatic breast cancer?
VP-16 and the combination of Vincristine and Adriamycin showed low response rates and no significant difference in survival in previously treated metastatic breast cancer.
Answers are grounded in this paper and cite their sources.
Neither regimen shows meaningful activity; confirms limited salvage options and supports novel-agent trials in refractory metastatic breast cancer.
39 previously treated patients with metastatic breast cancer were treated in a partially randomized study evaluating VP-16 and the combination of Vincristine (VCR) and Adriamycin (ADR). Of the 19 patients treated with VP-16 initially, two had partial remissions. No responses were noted in eleven patients who corssed-over after failing VCR plus ADR. Of the 20 patients treated with VCR plus ADR initially, four patients had partial responses. An additional 2/15 patients responded on crossover after failing initially on VP-16. No significant differences in time to last follow-up or death could be detected between the two treatment programs.
No takes yet. Share an insight, caveat, or question.
Eagan et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: